retatrutide phase 2 results 2024 2025 press release clinical trial Lilly, with new data, to seek FDA approval of obesity drug June 8, 2026: Reckless physicians – A New Obesity Drug Delivered

The available evidence indicates quite convincingly that SSRI use may play a causal role in upper gastrointestinal bleeding and that these drugs may act synergistically with other bleeding risk-increasing medications such as NSAIDs or low-dose aspirinPatients should be informed about the likelihood of possible upper gastrointestinal bleeding and high-risk patients should be followed closely. Psychiatric Drugs and ALS A research team at the Karolinska Institute in Sweden announced a worrisome drug complication ( JAMA Network Open , June 4, 2025)

Sikiric, P., Seiwerth, S., Rucman, R., Drmic, D., Stupnisek, M., Kokot, A.,

Given the rising burden of obesity, this chronic disease is going to be managed by specialists of many stripes beyond primary care and endocrinology, he said

If side effects are minimal, it may indicate weak receptor activation and limited efficacy